Dr. McKay Discusses Dutasteride in Prostate Cancer

Rana R. McKay, MD
Published: Thursday, Feb 20, 2014

Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, Boston, Massachusetts, explains the mechanism of action of dutasteride and its role in a phase II trial in which abiraterone acetate was combined with dutasteride in men with metastatic castration resistant prostate cancer (mCRPC).

McKay says dutasteride is a dual 5-α reductase inhibitor that prevents the conversion of testosterone to DHT, a more potent androgen.

Dutasteride is classically used for people with benign prostatic hypertrophy but was used in this phase II trial to try to decrease levels of DHT.
Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, Boston, Massachusetts, explains the mechanism of action of dutasteride and its role in a phase II trial in which abiraterone acetate was combined with dutasteride in men with metastatic castration resistant prostate cancer (mCRPC).

McKay says dutasteride is a dual 5-α reductase inhibitor that prevents the conversion of testosterone to DHT, a more potent androgen.

Dutasteride is classically used for people with benign prostatic hypertrophy but was used in this phase II trial to try to decrease levels of DHT.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x